176 related articles for article (PubMed ID: 28976412)
1. Switch From Originator to Equivalent Drug in the Era of Generic Antiepileptic Drugs: Study of Keppra Versus Epitiram Clinical Equivalence.
Fanella M; Morano A; Fattouch J; Albini M; Basili LM; Casciato S; Manfredi M; Giallonardo AT; Di Bonaventura C
Clin Neuropharmacol; 2017; 40(6):239-242. PubMed ID: 28976412
[TBL] [Abstract][Full Text] [Related]
2. Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting.
Reimers A; Olsson P; Nilsson J; Hoff E; Reis M; Strandberg M; Lundgren A; Källén K
Epilepsy Res; 2017 Aug; 134():54-61. PubMed ID: 28595756
[TBL] [Abstract][Full Text] [Related]
3. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
[TBL] [Abstract][Full Text] [Related]
4. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
5. Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.
Vari MS; Pinto F; Mencaroni E; Giudizioso G; Minetti C; La Neve A; Francavilla T; Piccioli M; Striano S; del Gaudio L; Tovo P; Striano P; Verrotti A
Clin Drug Investig; 2016 Jan; 36(1):87-91. PubMed ID: 26507620
[TBL] [Abstract][Full Text] [Related]
6. Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study.
Trimboli M; Russo E; Mumoli L; Tripepi G; Fortunato F; Mastroianni G; Abate F; De Sarro G; Gambardella A; Labate A
Eur J Neurol; 2018 Apr; 25(4):666-671. PubMed ID: 29322654
[TBL] [Abstract][Full Text] [Related]
7. Quality of life after switching to generic levetiracetam - A prospective comparative study.
Olsson P; Reimers A; Källén K
Epilepsy Behav; 2019 Jul; 96():169-174. PubMed ID: 31150996
[TBL] [Abstract][Full Text] [Related]
8. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
Contin M; Alberghini L; Candela C; Benini G; Riva R
Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
[TBL] [Abstract][Full Text] [Related]
9. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.
Bosak M; Słowik A; Turaj W
Drug Des Devel Ther; 2017; 11():2287-2291. PubMed ID: 28814836
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers].
Auriel E; Chistik V; Blatt I; Margolin N; Neufeld M
Harefuah; 2007 Apr; 146(4):269-71, 318. PubMed ID: 17476932
[TBL] [Abstract][Full Text] [Related]
11. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with generic levetiracetam in people with epilepsy.
Chaluvadi S; Chiang S; Tran L; Goldsmith CE; Friedman DE
Epilepsia; 2011 Apr; 52(4):810-5. PubMed ID: 21426334
[TBL] [Abstract][Full Text] [Related]
13. Brand name to generic substitution of levetiracetam in patients with epilepsy.
Gha-Hyun L; Dae SJ
Seizure; 2018 Aug; 60():127-131. PubMed ID: 29960217
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study.
Alsaadi TM; Shatzel A; Marquez AV; Jorgensen J; Farias S
Seizure; 2005 Mar; 14(2):139-42. PubMed ID: 15694569
[TBL] [Abstract][Full Text] [Related]
15. Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
van Vliet EA; Edelbroek PM; Gorter JA
Epilepsia; 2010 Mar; 51(3):362-70. PubMed ID: 19674045
[TBL] [Abstract][Full Text] [Related]
16. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam monotherapy for newly diagnosed epilepsy patients.
Alsaadi TM; Thieman C
Seizure; 2003 Apr; 12(3):154-6. PubMed ID: 12651080
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam monotherapy for late poststroke seizures in the elderly.
Kutlu G; Gomceli YB; Unal Y; Inan LE
Epilepsy Behav; 2008 Oct; 13(3):542-4. PubMed ID: 18539085
[TBL] [Abstract][Full Text] [Related]
19. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.
Rosenow F; Schade-Brittinger C; Burchardi N; Bauer S; Klein KM; Weber Y; Lerche H; Evers S; Kovac S; Hallmeyer-Elgner S; Winkler G; Springub J; Niedhammer M; Roth E; Eisensehr I; Berrouschot J; Arnold S; Schröder M; Beige A; Oertel WH; Strzelczyk A; Haag A; Reif PS; Hamer HM;
J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1093-8. PubMed ID: 22595362
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication.
May TW; Rambeck B; Jürgens U
Ther Drug Monit; 2003 Dec; 25(6):690-9. PubMed ID: 14639055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
